Should you buy Novartis stock now?
No, the technical signal for Novartis is currently Strong Sell. Novartis trades at $140.79 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -2.239 with rising momentum (signal: -2.516); RSI is at 40.2 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $156.29 points to 11.0% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Novartis stock?
The average analyst price target for Novartis is $156.29. The current price is $140.79, which gives an upside of 11.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $140.66 and $171.92.
Is Novartis a dividend stock?
Yes, Novartis is a dividend stock with a dividend yield of 3.23%. The latest dividend was $4.77 per share. The latest ex-dividend date (traded without the dividend) was Mar 11, 2026. The payout ratio is 57.2%, which is considered moderate.
When does Novartis pay a dividend in 2026?
The next dividend date for Novartis has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was Mar 11, 2026. The latest dividend was $4.77 per share with an ex-dividend date of Mar 11, 2026. The dividend yield is 3.23%. The payout ratio of 57.2% points to moderate dividend coverage.
What is the risk of Novartis stock?
Novartis is rated as a stock in the risk category Balanced. the annual standard deviation is 26.3%, which classifies the stock as Balanced.
Is Novartis overvalued?
No, Novartis is considered undervalued based on the analyst price target (11.0% upside). Novartis has the following valuation ratios: a P/E ratio of 22.2 (moderately to highly valued), a P/S ratio of 4.9, a P/B ratio of 6.5. The analyst price target suggests that the stock is undervalued by 11.0%.
Is Novartis overbought?
No, Novartis is not overbought. RSI is at 40.2 (neutral zone). The technical indicators show: RSI is at 40.2 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.2% below the 20-day average (short-term downtrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Novartis earnings report?
Novartis reports its next earnings on October 27, 2026. The stock currently trades at $140.79. With a P/E ratio of 22.2, the market will be watching closely whether earnings meet expectations.
Is Novartis shorted?
Novartis has minimal short interest of 0.27% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Novartis stock?
Yes, insiders are net buyers of Novartis – they are buying more shares than they are selling. Across the last 20 reported transactions, the split is 3 purchases and 17 sales, with a net 56,881,104 $ bought. Active buyers include Novartis Bioventures Ltd. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Novartis a good stock?
Based on our total score, Novartis is rated as a mediocre stock with a total score of 57 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 42/100, Quality: 79/100, Momentum: 51/100. In addition: analysts see 11.0% upside to the price target; a dividend of 3.23%; technical signal: Strong Sell. Whether Novartis is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Novartis stock?
The outlook for Novartis based on current data: the average analyst price target is $156.29 (+11.0%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Oct 27, 2026, which can move the price; the P/E ratio is 22.2 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Novartis stock moving?
Novartis is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Novartis go?
The average analyst price target for Novartis is $156.29, which corresponds to a potential gain of 11.0% from the current price of $140.79. The stock has traded between $117.98 and $165.43 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Novartis fall?
The stock has traded as low as $117.98 over the last 52 weeks — that is 16.2% below the current price of $140.79. The biggest decline (drawdown) in the same period was 28.7% from high to low. Within a year, the price typically swings about ±26.3% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Novartis do?
Novartis (ticker: NVS.US) researches, develops, and sells medicines around the world. The company makes money by creating and selling pharmaceutical treatments for complex diseases.
Novartis is best known for medicines that treat heart problems, such as Entresto, and autoimmu... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Novartis as an investment.
Did Novartis raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Novartis. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Novartis making money or losing money?
Yes, Novartis is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 22.5% — which is excellent. The operating margin (profit before interest and taxes) is 34.6%. At a P/E ratio of 22.2, you currently pay 22.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Novartis go bankrupt?
The bankruptcy risk of Novartis is rated as moderate. Altman Z2 (a model for assessing financial distress) is 2.30 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 132% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Novartis have a lot of debt?
Novartis has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 132%. For the healthcare sector, 80-150% counts as a typical level. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Novartis service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 10.2x, and net debt equals 1.8 years of earnings (EBITDA).
